Protective Effects of MC-1 Shown in CABG Patients

 

November 6, 2006

Results from the Phase II MEND-CABG study — which looked at demonstrated the clinical benefits of MC-1 in reducing cardiovascular events in patients undergoing coronary artery bypass graft (CABG) surgery — will be presented during the 2006 Scientific Sessions of the American Heart Association (AHA), to be held Nov. 12-15, 2006 in Chicago.

Medicure Inc., the cardiovascular-focused biopharmaceutical company that produced MC-1, says the study, which included 901 patients and was completed this year, will be presented by Dr. Michel Carrier, director of Cardiovascular Surgery Program, Montreal Heart Institute (MHI) between 3 and 4:30 p.p. Central Time, Sunday Nov. 12 in a poster session in Hall A2 of the McCormick Place Convention Center.

The abstract is titled, "Protective Effect of Pyridoxal-5-phosphate on Perioperative Myocardial Infarction is not Dependent of Aortic Cross Clamp Time: Results from the MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Trial.”